Straumann Holding AGXSWX:STMN +1.50%100 Debt-to-Equity is 0.19 as of Dec. 2025, which is 30% below its 10-year median of 0.27. GuruFocus rates XSWX:STMN with a GF Score™ of 100/100 and a GF Value™ of CHF137.43 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 704 Medical Devices & Instruments companies, Straumann Holding AG ranks better than 53.98% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Straumann Holding AG's Debt-to-Equity or its related term are showing as below:
XSWX:STMN'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.17 Med: 0.27 Max: 0.6
Current: 0.19
During the past 13 years, the highest Debt-to-Equity Ratio of Straumann Holding AG was 0.60. The lowest was 0.17. And the median was 0.27.
XSWX:STMN's Debt-to-Equity is ranked better than 53.98% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.225
vs XSWX:STMN: 0.19
Straumann Holding AG (XSWX:STMN) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Straumann Holding AG Debt-to-Equity Related Terms
Straumann Holding AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Straumann Holding AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:STMN vs ISRG, BDX, MDLN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Straumann Holding AG (XSWX:STMN) has a Debt-to-Equity of 0.19 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Straumann Holding AG and its competitors. This is 30% below median its historical median of 0.27. Over the past decade, Straumann Holding AG's Debt-to-Equity has ranged from 0.17 to 0.60. According to the industry distribution chart, Straumann Holding AG ranks #324 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 46%.
Is Straumann Holding AG's Debt-to-Equity too high?
Straumann Holding AG's current Debt-to-Equity of 0.19 is 30% below median its 10-year median of 0.27. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 0.60. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Straumann Holding AG's value of 0.19 is 15.6% below this industry median. Based on the distribution chart, Straumann Holding AG ranks #324 out of 704 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Straumann Holding AG has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #324 out of 704 companies for Debt-to-Equity. This puts Straumann Holding AG in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Straumann Holding AG's value of 0.19 is 15.6% below this benchmark. Historically, Straumann Holding AG's own Debt-to-Equity has ranged from 0.17 to 0.60 over the past decade. While the company's 10-year median is 0.27 vs. the industry median of 0.23, Straumann Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Straumann Holding AG's current Debt-to-Equity of 0.19 is 15.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Straumann Holding AG and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current Debt-to-Equity is 0.19, which is 30% below median its own 10-year median of 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Straumann Holding AG (XSWX:STMN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF137.43, compared to a current price of CHF105.20 — trading 23.5% below its estimated fair value. The current Debt-to-Equity is 0.19, which is 30% below median its 10-year median of 0.27 and 15.6% below the Medical Devices & Instruments industry median of 0.23. Straumann Holding AG's overall GF Score™ is 100/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Straumann Holding AG (XSWX:STMN), the current Debt-to-Equity is 0.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (XSWX:STMN) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of CHF105.20 is trading 23.5% below its estimated GF Value™ of CHF137.43.
GuruFocus considers Straumann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:STMN:
Debt-to-Equity: 0.19 (30% below median its 10-year median of 0.27)
GF Value™: CHF137.43 vs. price of CHF105.20 (23.5% below fair value)
Industry Position: 15.6% below the Medical Devices & Instruments median (#324 of 704)
No single metric tells the full story. See the XSWX:STMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
100GF Score
Get the complete analysis for XSWX:STMN
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:STMN has been successfully added to your 
